secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aspire Biopharma Holdings, Inc. (ASBP)
CIK:        0001847345
Form:       8-K
Filed at:   2026-09-09T14:10:13+00:00
Accession:  0001493152-26-041918
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 5.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aspire-Lakewood (ASBP) approves $10M buyback; DCSC 2025 revenue $209.5M, EBITDA $22.3M
--------------------------------------------------------------------------------

- Name changed to Aspire-Lakewood Holdings, Inc. effective Sept 8, 2026; ticker remains ASBP.
- Board authorized $10M common stock repurchase program effective Sept 9, 2026.
- DCSC FY2025 revenue ~$209.5M, Adjusted EBITDA $22.3M; H1 2026 revenue $103.9M, EBITDA $10.5M.
- ~1.5M shares outstanding as of Sept 8, 2026; 2025 Adjusted EBITDA ~$15.00 per share.
- CEO cites strong cash flow and undervaluation; buyback may be open market or private transactions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1847345/000149315226041918/0001493152-26-041918-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1847345/000149315226041918/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-041918

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer